VanEck Pharmaceutical ETF
PPH
63 hedge funds and large institutions have $59.9M invested in VanEck Pharmaceutical ETF in 2021 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 12 increasing their positions, 15 reducing their positions, and 4 closing their positions.
300% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 4
24% more funds holding
Funds holding: 51 → 63 (+12)
5% more capital invested
Capital invested by funds: $57.2M → $59.9M (+$2.77M)
1.12% less ownership
Funds ownership: 18.09% → 16.97% (-1.1%)
20% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 15
74% less call options, than puts
Call options by funds: $369K | Put options by funds: $1.41M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LJAC
L.J. Altfest & Co
New York
|
+$3.85M |
| 2 |
IMC Chicago
Chicago,
Illinois
|
+$1.82M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.06M |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$935K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$765K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$6.28M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.12M |
| 3 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$1.73M |
| 4 |
Morgan Stanley
New York
|
-$1.39M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1M |
PPH Hedge Fund Activity: Q4 2021 in Review
63 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2021, worth a combined $59.9M — up 4.8% from $57.2M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new PPH positions and 4 closed out — a net gain of 12 holders — while 12 added to existing stakes and 15 trimmed.
The largest buyer was L.J. Altfest & Co, opening a new position worth an estimated $3.85M. The largest seller was Bank of America, cutting an estimated $6.28M.
- 63 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2021, up from 51 in Q3 2021.
- Funds reported $59.9M of VanEck Pharmaceutical ETF stock for Q4 2021, up 4.8% quarter-over-quarter.
- 16 funds opened new VanEck Pharmaceutical ETF positions in Q4 2021 and 4 closed out, a net change of +12 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q4 2021 was L.J. Altfest & Co, an estimated $3.85M added.
- The largest VanEck Pharmaceutical ETF seller in Q4 2021 was Bank of America, an estimated $6.28M sold.
Based on aggregated 13F filings for Q4 2021.